Exciting Update from Longeveron: Embarking on a Journey to Transform Lives!
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace yourselves for groundbreaking news from Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR), a visionary clinical-stage biotechnology company on a mission to revolutionize healthcare. Longeveron, dedicated to developing cutting-edge cellular therapies for life-threatening and age-related conditions like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty, is thrilled to announce the launch of an extraordinary opportunity.
Today marks the commencement of the subscription period for the highly anticipated rights offering, a move that underscores Longeveron’s commitment to transforming lives through innovation. With each share priced at an accessible $3.00, this isn’t just an investment—it’s a chance to be part of a remarkable journey. The clock is ticking, as the subscription period will culminate at 5:00 p.m. Eastern Time on Thursday, September 21, 2023. And guess what? Longeveron might just extend this window of opportunity at their sole discretion, so stay tuned.
But that’s not all. Longeveron has unveiled a partnership with the esteemed R.F. Lafferty & Co., Inc., who will serve as the dealer-manager for this monumental offering. Brokers, take note—R.F. Lafferty & Co., Inc. is your go-to contact for this extraordinary venture.
Now, let’s address the elephant in the room. You might wonder, what about legality and transparency? Fret not. Longeveron’s got it covered. This press release isn’t a mere sales pitch; it’s a pledge of utmost integrity. There won’t be any hasty sales in states or jurisdictions where it’s not above board. Here’s the kicker: A registration statement concerning the rights was filed with the Securities and Exchange Commission and got the green light on August 14, 2023. This ensures that everything is by the book.
So, what’s the bottom line? Get ready to be part of history. Longeveron is more than a company; it’s a movement. A beacon of hope and progress in healthcare. For those stockholders and participating warrant holders in the know, the prospectus with all the nitty-gritty details awaits, a testament to Longeveron’s commitment to transparency.
Get ready, get set, and join Longeveron on this exhilarating ride towards a future where innovation knows no bounds. Your journey to transform lives starts now.
About Longeveron Inc.
Longeveron, a trailblazing biotech firm, is at the forefront of medical innovation, crafting regenerative marvels to tackle the most elusive medical challenges. At the heart of their groundbreaking pursuits lies Lomecel-B™ – a captivating alchemical concoction derived from the marrow of vibrant young donors.
This elixir of possibilities, with its multifaceted abilities, dances between the realms of bolstering vasculature, orchestrating regeneration, silencing inflammation, and orchestrating a symphony of tissue repair. Its promise spans across a kaleidoscope of ailments, painting a tapestry of hope. Longeveron’s grand stage is set, as Lomecel-B™ takes center spotlight, waltzing through clinical trials for the likes of hypoplastic left heart syndrome, the enigma of Alzheimer’s, and the delicate frailty of aging.
About R.F. Lafferty & Co., Inc.
R.F. Lafferty stands as a dynamic broker-dealer, a financial force that transcends time. With roots tracing back to 1946, this firm has etched a legacy by treating each client as a cherished masterpiece. A torch of tradition, now carried by a new generation, illuminates pathways to financial brilliance. The heart of R.F. Lafferty beats with independence, a family’s embrace, as it weaves connections with the world. An orchestra of experience conducts symphonies of service, harmonizing with unwavering dedication. Amidst the ever-shifting tides of the industry, R.F. Lafferty is the lighthouse guiding clients forward. Its pledge is unchanging: unmatched service, a compass guiding success, wielded by skilled artisans armed with knowledge, tools, and a treasury of offerings for the modern age.
In the realm of possibilities, this press release paints a canvas of forward-looking statements, a glimpse into a future sculpted by the currents of innovation. Guided by the sheltering embrace of the Private Securities Litigation Reform Act of 1995, these statements emanate from the heart of management’s vision. They dance with the rhythms of anticipation, weaving a tale of what could be, of operations that lie ahead, of performances yet to unfold.
Yet, like stars in the night sky, these statements twinkle with risks and uncertainties, reminders that the tapestry of reality is woven with both dreams and challenges. The words “believe,” “expects,” “may,” and their companions form a symphony of intent, while the shadow of strategy, goals, and tomorrows yet to come provides a backdrop for discussion.
This narrative of potentiality casts a spotlight on factors shaping the stage: the securities offered, the scientific voyage of Longeveron’s clinical trials, and the hopes riding on safety and efficacy. The market, a sea of patients and possibilities, stands as an uncharted realm, impacted by the currents of competition, the magic of therapeutic effects, and the dance with regulatory approval across borders.
In this story, the Company, a protagonist, navigates challenges, contemplates the tapestry of intellectual property, and grapples with the ever-present need for capital. The script acknowledges the ebb and flow of the financial tide, and while the tale carries the weight of SEC filings and the Company’s journey, the pen of intention remains firm – to carve a path forward, to weave a future, to paint dreams into reality.
Dated not merely in ink, but in possibility, this press release casts its echo into the future, a reminder that the world of finance is not etched in stone but sculpted in the clay of endeavors.